Please use this identifier to cite or link to this item:
Full metadata record
|dc.description.abstract||Background: Hyperhomocysteinaemia is a factor related to the development of atherosclerosis in rheumatoid arthritis (RA). However, Hispanics with RA develop high rates of coronary disease; there are no studies about the frequency and factors related to high levels of homocysteine in Mexican patients. Objective: To evaluate the prevalence and characteristics associated with hyperhomocysteinaemia in Mexican patients with RA. Methods: One hundred and fifty-two patients with RA were compared with 153 controls. The assessment in RA included clinical characteristics, disease activity (RADAR), functioning (HAQ-Di and global functional status), comorbidity, and radiological damage. Laboratory determinations included total serum homocysteine (tHcy), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and lipid profile. Results: Median levels of homocysteine were higher in RA compared with controls (11.3 vs. 9.3, p < 0.001). Twenty per cent of the patients with RA had hyperhomocysteinaemia (> 15 μmol/L) compared with 6% in controls (p < 0.001). There was statistical association between hyperhomocysteinaemia in RA with male gender (p < 0.001), impairment in the global functional status (p=0.004), higher radiological damage (p=0.001), and CRP (p=0.04). There was no association with RADAR, HAQ-Di, or RF, methotrexate dose or duration of use. In the adjusted multivariate model, the two variables associated with higher risk for hyperhomocysteinaemia were male gender (OR=4.2, 95% CI 2 to 12, p=0.006) and higher radiological damage (III-IV) (OR=3.4, 95% CI 1.3 to 9, p=0.01). Conclusions: Our data show a high prevalence of hyperhomocysteinaemia in Mexican patients with RA. More effort is required to evaluate and treat earlier this coronary risk factor. © 2006 Taylor & Francis on license from Scandinavian Rheumatology Research Foundation.|
|dc.title||Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis|
|dc.relation.ispartofjournal||Scandinavian Journal of Rheumatology|
|dc.contributor.affiliation||Lopez-Olivo, M.A., Department of Internal Medicine - Rheumatology, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Mexico; Gonzalez-Lopez, L., Department of Internal Medicine - Rheumatology, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Mexico, Salto del Agua 2192, Col. Jardines del Country, Guadalajara, Jalisco, CP 44210, Mexico; Garcia-Gonzalez, A., Baylor College of Medicine, Houston, TX, United States; Villa-Manzano, A.I., Department of Internal Medicine - Rheumatology, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Mexico; Cota-Sanchez, A.R., Department of Blood Chemistry, Central Laboratory, Centro Médico Nacional de Occidente, Guadalajara, Mexico; Salazar-Paramo, M., Section of Studies for Musculoskeletal and Autoimmune Diseases, Clinical Epidemiology Research Unit, Hospital de Especialidades, Guadalajara, Mexico; Varon-Villalpando, E., Department of Clinical Pathology, Hospital General Regional 110, IMSS, Guadalajara, Mexico; Cardona-Muñoz, E.G., Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Mexico; Gamez-Nava, J., Section of Studies for Musculoskeletal and Autoimmune Diseases, Clinical Epidemiology Research Unit, Hospital de Especialidades, Guadalajara, Mexico|
|Appears in Collections:||Producción científica UdeG (prueba)|
Files in This Item:
There are no files associated with this item.
Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.